|Bid||224.54 x 800|
|Ask||224.81 x 1000|
|Day's Range||224.24 - 242.44|
|52 Week Range||64.88 - 290.23|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||278.41|
There's little doubt that the digital signature market got a big boost from the pandemic, and as the industry leader, DocuSign (NASDAQ: DOCU) was a major beneficiary. During the first nine months of 2020, revenue grew 46% year over year, while the company's operating loss edged lower. While DocuSign's dominance of the e-signature space still represents a significant market opportunity, there's another one that's just as big waiting in the wings.
I regret not buying the leader in signatures and the top dog in refrigerated pet food. Let's change the narrative.
DocuSign (Nasdaq: DOCU) today announced that it will host its inaugural Analyst Day on Wednesday, March 24, 2021 in conjunction with its customer conference, Momentum. The Analyst Day event will begin at 11:00 a.m. PT/2:00 p.m. ET, following the Momentum keynote presentation. Members of the DocuSign management team will discuss the company's vision, market opportunities, product innovation, go-to-market strategy, and financial outlook, followed by a Q&A session.